Alatawi, Y.; Alanazi, F.E.; Alattar, A.; Alshaman, R.; Ramadan, Y.N.; Sayad, R.; Hetta, H.F.
Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis. Pharmaceuticals 2025, 18, 1674.
https://doi.org/10.3390/ph18111674
AMA Style
Alatawi Y, Alanazi FE, Alattar A, Alshaman R, Ramadan YN, Sayad R, Hetta HF.
Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis. Pharmaceuticals. 2025; 18(11):1674.
https://doi.org/10.3390/ph18111674
Chicago/Turabian Style
Alatawi, Yasser, Fawaz E. Alanazi, Abdullah Alattar, Reem Alshaman, Yasmin N. Ramadan, Reem Sayad, and Helal F. Hetta.
2025. "Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis" Pharmaceuticals 18, no. 11: 1674.
https://doi.org/10.3390/ph18111674
APA Style
Alatawi, Y., Alanazi, F. E., Alattar, A., Alshaman, R., Ramadan, Y. N., Sayad, R., & Hetta, H. F.
(2025). Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis. Pharmaceuticals, 18(11), 1674.
https://doi.org/10.3390/ph18111674
